- Home
- LYRA vs MTVA Comparison
LYRA vs MTVA Comparison
Compare LYRA & MTVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYRA
- MTVA
- Stock Information
- Founded
- LYRA 2005
- MTVA 2014
- Country
- LYRA United States
- MTVA United States
- Employees
- LYRA N/A
- MTVA N/A
- Industry
- LYRA Medical/Dental Instruments
- MTVA
- Sector
- LYRA Health Care
- MTVA
- Exchange
- LYRA Nasdaq
- MTVA NYSE
- Market Cap
- LYRA 15.0M
- MTVA 14.3M
- IPO Year
- LYRA 2020
- MTVA N/A
- Fundamental
- Price
- LYRA $9.15
- MTVA $0.67
- Analyst Decision
- LYRA Buy
- MTVA Strong Buy
- Analyst Count
- LYRA 2
- MTVA 2
- Target Price
- LYRA $16.00
- MTVA $7.50
- AVG Volume (30 Days)
- LYRA 288.0K
- MTVA 121.8K
- Earning Date
- LYRA 08-13-2025
- MTVA 08-13-2025
- Dividend Yield
- LYRA N/A
- MTVA N/A
- EPS Growth
- LYRA N/A
- MTVA N/A
- EPS
- LYRA N/A
- MTVA N/A
- Revenue
- LYRA $1,185,000.00
- MTVA N/A
- Revenue This Year
- LYRA N/A
- MTVA N/A
- Revenue Next Year
- LYRA $1,286.17
- MTVA N/A
- P/E Ratio
- LYRA N/A
- MTVA N/A
- Revenue Growth
- LYRA N/A
- MTVA N/A
- 52 Week Low
- LYRA $3.81
- MTVA $0.63
- 52 Week High
- LYRA $37.50
- MTVA $5.16
- Technical
- Relative Strength Index (RSI)
- LYRA 44.26
- MTVA N/A
- Support Level
- LYRA $8.35
- MTVA N/A
- Resistance Level
- LYRA $9.36
- MTVA N/A
- Average True Range (ATR)
- LYRA 1.25
- MTVA 0.00
- MACD
- LYRA -0.72
- MTVA 0.00
- Stochastic Oscillator
- LYRA 9.95
- MTVA 0.00
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
About MTVA METAVIA INC
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.